Literature DB >> 25723109

Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Cristina R Antonescu1, Albert J H Suurmeijer, Lei Zhang, Yun-Shao Sung, Achim A Jungbluth, William D Travis, Hikmat Al-Ahmadie, Christopher D M Fletcher, Rita Alaggio.   

Abstract

Approximately 50% of conventional inflammatory myofibroblastic tumors (IMTs) harbor ALK gene rearrangement and overexpress ALK. Recently, gene fusions involving other kinases have been implicated in the pathogenesis of IMT, including ROS1 and in 1 patient PDGFRB. However, it remains uncertain whether the emerging genotypes correlate with clinicopathologic characteristics of IMT. In this study, we expand the molecular investigation of IMT in a large cohort of different clinical presentations and analyze for potential genotype-phenotype associations. Criteria for inclusion in the study were typical morphology and tissue availability for molecular studies. The lack of ALK immunoreactivity was not an excluding factor. As overlapping gene fusions involving actionable kinases are emerging in both IMT and lung cancer, we set out to evaluate abnormalities in ALK, ROS1, PDGFRB, NTRK1, and RET by fluorescence in situ hybridization. In addition, next-generation paired-end RNA sequencing and FusionSeq algorithm was applied in 4 cases, which identified EML4-ALK fusions in 2 cases. Of the 62 IMTs (25 children and 37 adults), 35 (56%) showed ALK gene rearrangement. Of note, EML4-ALK inversion was noted in 7 (20%) cases, seen mainly in the lung and soft tissue of young children including 2 lesions from newborns. There were 6 (10%) ROS1-rearranged IMTs, all except 1 presenting in children, mainly in the lung and intra-abdominally and showed a distinctive fascicular growth of spindle cells with long cell processes, often positive for ROS1 immunohistochemistry. Two of the cases showed TFG-ROS1 fusions. Interestingly, 1 adult IMT revealed a RET gene rearrangement, a previously unreported finding. Our results show that 42/62 (68%) IMTs are characterized by kinase fusions, offering a rationale for targeted therapeutic strategies. Interestingly, 90% of fusion-negative IMTs were seen in adults, whereas >90% of pediatric IMT showed gene rearrangements. EML4-ALK inversion and ROS1 fusions emerge as common fusion abnormalities in IMT, closely recapitulating the pattern seen in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25723109      PMCID: PMC4465992          DOI: 10.1097/PAS.0000000000000404

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.

Authors:  Gaëlle Pierron; Franck Tirode; Carlo Lucchesi; Stéphanie Reynaud; Stelly Ballet; Sarah Cohen-Gogo; Virginie Perrin; Jean-Michel Coindre; Olivier Delattre
Journal:  Nat Genet       Date:  2012-03-04       Impact factor: 38.330

2.  Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.

Authors:  Larisa V Debelenko; Diane C Arthur; Svetlana D Pack; Lee J Helman; David S Schrump; Maria Tsokos
Journal:  Lab Invest       Date:  2003-09       Impact factor: 5.662

3.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

4.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

Authors:  Christine M Lovly; Abha Gupta; Doron Lipson; Geoff Otto; Tina Brennan; Catherine T Chung; Scott C Borinstein; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Cheryl M Coffin
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

5.  Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.

Authors:  Jan Cools; Iwona Wlodarska; Riet Somers; Nicole Mentens; Florence Pedeutour; Brigitte Maes; Christiane De Wolf-Peeters; Patrick Pauwels; Anne Hagemeijer; Peter Marynen
Journal:  Genes Chromosomes Cancer       Date:  2002-08       Impact factor: 5.006

6.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

Authors:  Yunjian Pan; Yang Zhang; Yuan Li; Haichuan Hu; Lei Wang; Hang Li; Rui Wang; Ting Ye; Xiaoyang Luo; Yiliang Zhang; Bin Li; Deng Cai; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Lung Cancer       Date:  2014-02-19       Impact factor: 5.705

7.  VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?

Authors:  Nathaniel E Smith; Andrea T Deyrup; Adrian Mariño-Enriquez; Jonathan A Fletcher; Julia A Bridge; Peter B Illei; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

8.  Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.

Authors:  Akihiko Sokai; Makiko Enaka; Risa Sokai; Shoichi Mori; Shunsuke Mori; Masaharu Gunji; Masahiko Fujino; Masafumi Ito
Journal:  Jpn J Clin Oncol       Date:  2013-11-24       Impact factor: 3.019

9.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

10.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Authors:  Danilo Maddalo; Eusebio Manchado; Carla P Concepcion; Ciro Bonetti; Joana A Vidigal; Yoon-Chi Han; Paul Ogrodowski; Alessandra Crippa; Natasha Rekhtman; Elisa de Stanchina; Scott W Lowe; Andrea Ventura
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

View more
  60 in total

1.  Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Authors:  Srikanth R Ambati; Emily K Slotkin; Edna Chow-Maneval; Ellen M Basu
Journal:  JCO Precis Oncol       Date:  2018-09-13

2.  EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Authors:  Fernando Vargas-Madueno; Edwin Gould; Raul Valor; Nhu Ngo; Linsheng Zhang; Miguel A Villalona-Calero
Journal:  Oncologist       Date:  2018-05-08

3.  For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.

Authors:  Diana Taheri; David J Zahavi; Maria Del Carmen Rodriguez; Abdelrazak Meliti; Neda Rezaee; Raluca Yonescu; Bernardo F P Ricardo; Shahaboddin Dolatkhah; Yi Ning; Justin A Bishop; George J Netto; Rajni Sharma
Journal:  Virchows Arch       Date:  2016-06-06       Impact factor: 4.064

4.  Pulmonary inflammatory myofibroblastic tumor versus IgG4-related inflammatory pseudotumor: differential diagnosis based on a case series.

Authors:  Longfei Zhu; Jian Li; Chengwu Liu; Wenshuang Ding; Feng Lin; Chenglin Guo; Lunxu Liu
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.

Authors:  Jennifer A Bennett; Valentina Nardi; Marjan Rouzbahman; Vicente Morales-Oyarvide; G Petur Nielsen; Esther Oliva
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

6.  Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Authors:  Srikanth R Ambati; Emily K Slotkin; Edna Chow-Maneval; Ellen M Basu
Journal:  JCO Precis Oncol       Date:  2018-09-13

7.  Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.

Authors:  Jason C Chang; Lei Zhang; Alexander E Drilon; Ping Chi; Rita Alaggio; Laetitia Borsu; Ryma Benayed; William D Travis; Marc Ladanyi; Cristina R Antonescu
Journal:  J Thorac Oncol       Date:  2018-12-11       Impact factor: 15.609

Review 8.  Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Authors:  Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck Pathol       Date:  2018-11-22

9.  Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.

Authors:  Brendan C Dickson; David Swanson; George S Charames; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

10.  Morphologic Overlap Between Inflammatory Myofibroblastic Tumor and IgG4-related Disease: Lessons From Next-generation Sequencing.

Authors:  Martin S Taylor; Abhijit Chougule; Allsion R MacLeay; Pawel Kurzawa; Ivan Chebib; Long Le; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2019-03       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.